1 Mibefradil is a novel Ca2+ antagonist which blocks both high-voltage acti
vated and low voltage-activated Ca2+ channels. Although L-type Ca2+ channel
block was demonstrated in functional experiments its molecular interaction
with the channel has not yet been studied. We therefore investigated the b
inding of [H-3]-mibefradil and a series of mibefradil analogues to L-type C
a2+ channels in different tissues.
2 [H-3]-Mibefradil labelled a single class of high affinity sites on skelet
al muscle L-type Ca2+ channels (K-D of 2.5 +/- 0.4 nM, B-max = 56.4 +/- 2.3
pmol mg(-1) of protein).
3 Mibefradil land a series of analogues) partially inhibited (+)-[H-3]-isra
dipine binding to skeletal muscle membranes but stimulated binding to brain
L-type Ca2+ channels and alpha 1C-subunits expressed in tsA201 cells indic
ating a tissue-specific, non-competitive interaction between the dihydropyr
idine and mibefradil binding domain.
4 [H-3]-Mibefradil also labelled a heterogenous population of high affinity
sites in rabbit brain which was inhibited by a series of nonspecific Ca2and Na+-channel blockers.
5 Mibefradil and its analogue RO40-6040 had high affinity for neuronal volt
age-gated Na+-channels as confirmed in binding (apparent K-i values of 17 a
nd 1.0 nM, respectively) and functional experiments (40% use-dependent inhi
bition of Na+-channel current by 1 mu M mibefradil in GH3 cells).
6 Our data demonstrate that mibefradil binds to voltage-gated L-type Ca2+ c
hannels with very high affinity and is also a potent blocker of voltage-gat
ed neuronal Na+-channels. More lipophilic mibefradil analogues may possess
neuroprotective properties like other nonselective Ca2+-/Na+-channel blocke
rs.